Vifor (International) Ltd. Discloses Stake in Cara Therapeutics
Ticker: TVRD · Form: SC 13D · Filed: Oct 30, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | SC 13D |
| Filed Date | Oct 30, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, schedule-13d, pharmaceuticals
Related Tickers: CARA
TL;DR
**Vifor (International) Ltd. just bought into Cara Therapeutics. Big move.**
AI Summary
On October 23, 2024, Vifor (International) Ltd. filed a Schedule 13D regarding Cara Therapeutics, Inc. The filing indicates a change in beneficial ownership, with Vifor (International) Ltd. now holding a significant stake in Cara Therapeutics. The specific percentage and number of shares are not detailed in this initial filing.
Why It Matters
This filing signals a potential shift in control or influence over Cara Therapeutics, which could impact its strategic direction and future operations.
Risk Assessment
Risk Level: medium — A Schedule 13D filing indicates a significant change in beneficial ownership, which can lead to activist investor behavior or a takeover, introducing uncertainty.
Key Players & Entities
- Vifor (International) Ltd. (company) — Filing entity
- Cara Therapeutics, Inc. (company) — Subject company
- Tinne Gilles (person) — Authorized contact for notices
- CSL Vifor (company) — Affiliated entity
- Vifor Pharma Management Ltd. (company) — Affiliated entity
FAQ
What is the exact percentage of Cara Therapeutics' stock now owned by Vifor (International) Ltd.?
The provided filing excerpt does not specify the exact percentage of Cara Therapeutics' stock owned by Vifor (International) Ltd.
When did the event requiring this filing occur?
The date of the event which requires filing of this statement is October 23, 2024.
What is the business address of Cara Therapeutics, Inc.?
The business address of Cara Therapeutics, Inc. is 400 Atlantic Street, Suite 500, Stamford, CT 06901.
Who is the person authorized to receive notices for this filing?
Tinne Gilles, General Counsel of CSL Vifor, is the person authorized to receive notices and communications.
What is the CUSIP number for Cara Therapeutics, Inc. common stock?
The CUSIP number for Cara Therapeutics, Inc. common stock is 140755109.
Filing Stats: 1,963 words · 8 min read · ~7 pages · Grade level 13.3 · Accepted 2024-10-30 16:21:50
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
Filing Documents
- d837152dsc13d.htm (SC 13D) — 57KB
- d837152dex991.htm (EX-99.1) — 37KB
- 0001193125-24-247585.txt ( ) — 96KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. VIFOR (INTERNATIONAL) LTD. Dated: October 30, 2024 By: /s/ Alexandros Sigalas Name: Alexandros Sigalas, Head of Finance, CSL Vifor Dated: October 30, 2024 By: /s/ Markus Frenzen Name: Markus Frenzen, Head, FP&A, CSL Vifor CSL LIMITED Dated: October 30, 2024 By: /s/ Fiona Mead Name: Fiona Mead, Company Secretary